ELI LILLY & Co (LLY)
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.
Address
LILLY CORPORATE CTR
INDIANAPOLIS, IN 46285
Founded
1876
Number of Employees
43,000
Website
http://www.lilly.com
Buyback
Buyback Data | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | Average |
---|---|---|---|---|---|---|---|---|---|---|---|---|
$ Amount Purchased ($ in 000s) |
$800 | $749 | $540 | $360 | $4,150 | $4,400 | $500 | $1,250 | $1,500 | $750 | - | $1,500 |
Average Price | $63.58 | $75.87 | $73.91 | $81.95 | $90.46 | $116.90 | $137.87 | $230.98 | $267.54 | $326.29 | - | $111.42 |
# Shares Purchased | 12,579 | 9,877 | 7,306 | 4,390 | 45,881 | 37,639 | 3,627 | 5,411 | 5,607 | 2,299 | - | 13,462 |
Buyback Performance | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | Average |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Total Return to Date | 1,351.8% | 1,116.5% | 1,148.9% | 1,026.3% | 920.4% | 689.6% | 569.5% | 299.6% | 245.0% | 182.9% | - | 728.4% |
S&P 500 Return to Date | 181.9% | 173.0% | 168.6% | 129.7% | 104.9% | 93.1% | 74.8% | 31.7% | 37.3% | 31.3% | - | 102.6% |
Excess Total Return | 1,170.0% | 943.5% | 980.3% | 896.6% | 815.5% | 596.5% | 494.6% | 268.0% | 207.7% | 151.5% | - | 625.8% |
Quartile Rank |
|
|
|
|
|
|
|
|
|
|
|
|
Percentile Rank | 98% | 98% | 98% | 99% | 99% | 98% | 97% | 98% | 98% | 99% | - | 99% |
Buyback returns calculated using weighted average buyback price over the last 10 years and comparing to current day stock price value. S&P 500 used as benchmark for excess return.
Insider Transactions
Filters
Keyboard Shortcuts: Show (a) | Close (Esc)